The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. Thirty-one patients with measurable, locoregional, or metastatic SCCHN were treated with docetaxel, ...

Philadelphia, November 12, 2024 – The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from ...

Docetaxel rechallenge was tied to improved overall survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) who did not experience disease progression on ...

Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with ...

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

Data from patients treated with neoadjuvant PTCH between January 2015 and December 2024 were retrospectively reviewed. The primary end point was the pathologic complete response (pCR) rate, with ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...